60 Degrees Pharmaceuticals (SXTP)

Executive Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for infectious diseases, with a primary emphasis on tropical diseases such as malaria. Its lead product, ARAKODA® (tafenoquine), is FDA-approved for malaria prophylaxis in adults and represents the company's sole commercial asset. Despite this approval, commercialization has been limited, and the company maintains a lean pipeline with ongoing development efforts for tafenoquine in additional indications, including potential use for malaria treatment or other anti-infective applications. As a small-cap public entity with a market capitalization of approximately $4 million, 60 Degrees Pharmaceuticals operates with a narrow focus and faces challenges in scaling revenue and advancing pipeline programs. Looking ahead, the company's strategy revolves around expanding the label for tafenoquine and pursuing strategic partnerships to unlock value. Key near-term catalysts include potential updates on clinical studies evaluating tafenoquine for new indications, announcements regarding licensing or co-development agreements, and progress in securing non-dilutive funding or government contracts. Given the company's limited resources and dependence on a single product, the success of these initiatives will be critical to its growth trajectory. While the risk profile remains elevated, successful execution could lead to significant upside from current valuation levels.

Upcoming Catalysts (preview)

• H2 2026Phase 2/3 data readout for tafenoquine in malaria treatment30% success
• Q3 2026Announcement of strategic partnership or licensing deal for ARAKODA40% success
• Q4 2026FDA label expansion for tafenoquine prophylaxis in pediatric population20% success